Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Delays Raise Death Risk in Kids with Status Epilepticus

Delays Raise Death Risk in Kids with Status Epilepticus

Action Points

  • Delay of ≥10 minutes after seizure onset in first-line benzodiazepine treatment of pediatric patients with refractory convulsive status epilepticus (SE) is associated with adverse short-term outcomes, including death, more frequent use of continuous infusions, longer seizure duration, and more frequent hypotension.
  • Note that these findings may change the perception of acute seizure and SE treatment, converting it into an extremely time-sensitive emergency similar to stroke or other cardiovascular events.

Delayed first-line treatment of refractory convulsive status epilepticus (SE) led to a higher frequency of death, a 5-year observational study from the Pediatric Status Epilepticus Research Group found.

Pediatric patients who received first-line benzodiazepine treatment 10 minutes or more after SE onset had a much higher chance of death (adjusted OR 11.0), greater odds of receiving continuous infusion (adjusted OR 1.8), longer convulsive seizure durations (adjusted OR 2.6), and more frequent hypotension (adjusted OR 2.3), reported Tobias Loddenkemper, MD, director of Clinical Epilepsy Research at Boston Children’s Hospital. and colleagues.

First-line treatment delays also were linked to delays in administering second- and third-line treatments.

“These findings may change the perception of acute seizure and status epilepticus treatment, tentatively converting it into an extremely time-sensitive emergency that is similar to stroke or other cardiovascular events,” the team wrote online in JAMA Neurology.

“This is the first pediatric study on refractory convulsive SE that demonstrates a link between delayed treatment and poor outcomes and suggests that timely treatment may be a method to prevent or improve such outcomes,” commented Anup D. Patel, MD, section chief of Neurology at Nationwide Children’s Hospital in Columbus, OH, writing in an accompanying editorial.

“Status epilepticus is life threatening and affects a high percentage of children. Both short-term and long-term morbidity and mortality risks are present for children who experience SE. Methods to improve these outcomes are thus desperately needed.”

Current SE treatment protocols recommend that patients receive first-line treatment — a benzodiazepine — within 5 to 10 minutes of seizure onset. This usually is followed by a second-line treatment of a non-benzodiazepine anti-seizure medication 10 to 20 minutes later. If SE persists, patients may receive a third-line treatment — anesthetic agents by continuous infusion — within 30 to 70 minutes of seizure onset.

The rationale is to stop seizures quickly and reduce the risk of brain damage and other complications. Studies have shown that seizures usually last less than 10 minutes; seizures lasting longer often do not stop spontaneously.

While time to treatment has been associated independently with SE duration, the effects on other outcome measurements like death were unknown.

To discover how timing mattered, Loddenkemper et al performed an observational study of 218 children admitted with refractory convulsive SE to 11 pediatric tertiary hospitals in the United States from June 1, 2011, to July 31, 2016. Patients were stratified into two groups: those who received timely first-line benzodiazepine (i.e., given within less than 10 minutes of seizure onset); and those who received treatment within 10 or more minutes.

Patients were ages 1 month to 21 years, had focal or generalized convulsive epileptic seizures at onset, and had treatment failure with two or more anti-seizure medications or started continuous infusion for seizure control.

The median age of the group was 4, and 53.2% were male. Of the 218 patients studied, 33.9% received first-line benzodiazepine treatment in less than 10 minutes, and 66.1% received it in 10 minutes or more. In 63.8% of patients, refractory convulsive SE started in a pre-hospital setting.

The median time to first-line benzodiazepine treatment was 17 minutes; it was longer in the pre-hospital group than the in-hospital cohort (25 minutes versus 8 minutes). The median time to the first administration of non-benzodiazepine anti-seizure medications was 63 minutes — that, too, was longer for the pre-hospital group (82 minutes) than the in-hospital group (40 minutes).

During hospital admission, seven patients (3.2%) died. All seven received untimely first-line benzodiazepine treatment, and five of the seven had pre-hospital SE onset. Multivariate analysis showed that untimely first-line benzodiazepine treatment had an adjusted OR of death of 11.0 (95% CI 1.43 to ∞; P=0.02.).

About half of the patients in the study — 112, or 51.4% — received a continuous infusion; of these, 71.4% had received untimely first-line treatment (P=0.09). The untimely treatment group was more likely to receive one or more continuous infusions (adjusted OR, 1.8; 95% CI 1.01-3.36; P=0.047).

The median convulsion duration was 48.5 minutes longer for patients who received untimely first-line benzodiazepine treatment (91 versus 139.5 minutes; P=0.03).

More work is needed to improve outcomes, especially in the pre-hospital setting, Patel noted: “Evidence-based guidelines exist for the pre-hospital treatment of seizures and most emergency medical services have independent protocols, but it is not known if these guidelines are implemented uniformly by emergency medical services personnel.

“Standardization of these protocols using guidelines may improve outcomes and is a good first step.”

The study has several limitations, the researchers noted. They did not determine the association between the dose of benzodiazepine and outcomes, and the small number of overall deaths in the study limited the number of confounders in the analysis; other confounders may have influenced mortality and other outcomes. In the pre-hospital setting, times to treatment were based on information provided by families, although the researchers corroborated data with emergency medical services reports and medical records when available.

In addition, the team said, the findings do not include patients whose seizures spontaneously stopped, or stopped after medication before coming to the hospital; the findings apply only to pediatric patients with refractory convulsive SE.

The study and the Pediatric Status Epilepticus Research Group consortium of 11 tertiary pediatric hospitals in the United States are funded by the Epilepsy Research Fund and the Pediatric Epilepsy Research Foundation.

The researchers reported financial relationships with Ovation Pharmaceuticals, King Pharmaceuticals, PRA International/Eisai, Johnson & Johnson, Lily, GlaxoSmithKline, Pfizer, Siemens, General Electric, Supernus, AssureX Health, Sage Therapeutics, GWPharm, Novartis, Lundbeck, Upsher-Smith, Acorda, and Zogenix.

Patel reported financial relationships with Greenwich Biosciences, UCB Pharma, Supernus, LivaNova, and Upsher-Smith.

2018-01-23T14:00:00-0500

Tagged with:

About author

Related Articles